D.A. Davidson & CO. increased its position in Merck & Company, Inc. (NYSE:MRK) by 16.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 433,599 shares of the company’s stock after buying an additional 62,265 shares during the period. Merck & Company accounts for approximately 0.7% of D.A. Davidson & CO.’s investment portfolio, making the stock its 28th largest position. D.A. Davidson & CO.’s holdings in Merck & Company were worth $27,056,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Solaris Asset Management LLC boosted its stake in Merck & Company by 3.8% in the third quarter. Solaris Asset Management LLC now owns 1,635 shares of the company’s stock worth $102,000 after buying an additional 60 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in Merck & Company by 5.9% in the second quarter. Acrospire Investment Management LLC now owns 1,800 shares of the company’s stock worth $104,000 after buying an additional 100 shares in the last quarter. Blume Capital Management Inc. boosted its stake in Merck & Company by 14.0% in the third quarter. Blume Capital Management Inc. now owns 1,710 shares of the company’s stock worth $107,000 after buying an additional 210 shares in the last quarter. Roble Belko & Company Inc boosted its stake in Merck & Company by 16.6% in the third quarter. Roble Belko & Company Inc now owns 2,102 shares of the company’s stock worth $131,000 after buying an additional 300 shares in the last quarter. Finally, NewSquare Capital LLC boosted its stake in Merck & Company by 3.9% in the third quarter. NewSquare Capital LLC now owns 2,187 shares of the company’s stock worth $137,000 after buying an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 74.10% of the company’s stock.

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Merck & Company, Inc. (NYSE:MRK) opened at 65.66 on Wednesday. The stock has a 50 day moving average price of $61.88 and a 200 day moving average price of $61.86. The firm has a market cap of $181.03 billion, a price-to-earnings ratio of 32.19 and a beta of 0.79. Merck & Company, Inc. has a 12 month low of $49.63 and a 12 month high of $65.72.

Merck & Company (NYSE:MRK) last issued its earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.00. The company earned $10.10 billion during the quarter, compared to analyst estimates of $10.22 billion. Merck & Company had a net margin of 14.30% and a return on equity of 24.08%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.93 EPS. On average, equities analysts expect that Merck & Company, Inc. will post $3.81 earnings per share for the current fiscal year.

“D.A. Davidson & CO. Buys 62,265 Shares of Merck & Company, Inc. (MRK)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/02/15/d-a-davidson-co-buys-62265-shares-of-merck-company-inc-mrk.html.

A number of analysts recently commented on the company. Vetr cut Merck & Company from a “hold” rating to a “sell” rating and set a $57.17 price objective for the company. in a research report on Wednesday, December 14th. Piper Jaffray Companies raised shares of Merck & Company from a “neutral” rating to an “overweight” rating and set a $72.00 price objective for the company in a research note on Thursday, January 12th. Guggenheim upgraded shares of Merck & Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $61.63 to $70.00 in a report on Thursday, January 12th. Zacks Investment Research raised shares of Merck & Company from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research report on Tuesday, December 6th. Finally, Jefferies Group LLC restated an “underperform” rating and issued a $48.00 target price on shares of Merck & Company in a report on Thursday, January 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $66.91.

In other news, EVP Michael J. Holston sold 91,959 shares of the business’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $63.96, for a total transaction of $5,881,697.64. Following the transaction, the executive vice president now owns 105,559 shares in the company, valued at approximately $6,751,553.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Patricia F. Russo sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 8th. The stock was sold at an average price of $64.42, for a total transaction of $322,100.00. Following the transaction, the director now owns 18,148 shares in the company, valued at approximately $1,169,094.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,959 shares of company stock valued at $6,843,448. 0.05% of the stock is owned by company insiders.

About Merck & Company

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.